Cargando…
In vivo assessment of a delayed release formulation of larazotide acetate indicated for celiac disease using a porcine model
There is no FDA approved therapy for the treatment of celiac disease (CeD), aside from avoidance of dietary gluten. Larazotide acetate (LA) is a first in class oral peptide developed as a tight junction regulator, which is a lead candidate for management of CeD. A delayed release formulation was tes...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041193/ https://www.ncbi.nlm.nih.gov/pubmed/33844694 http://dx.doi.org/10.1371/journal.pone.0249179 |